Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD-alphaGITR
- Development stage
- Preclinical
- Lead developer
- University of Alabama at Birmingham
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CBD-alphaGITR is an engineered collagen-binding monoclonal antibody designed to target the Glucocorticoid-induced TNFR-related protein (GITR) specifically within the tumor microenvironment. It consists of an anti-GITR antibody conjugated to the collagen-binding domain (CBD) derived from von Willebrand Factor (vWF), which enables selective accumulation in tumors expressing high levels of Collagen type I and III, such as recurrent glioblastoma (rGBM), while sparing normal brain tissue. By agonistically targeting GITR, the drug reduces the population of regulatory T cells (Tregs) and exhausted CD8+ T cells, thereby remodeling the immunosuppressive microenvironment and enhancing anti-tumor immune responses. It has shown significant efficacy in preclinical models of rGBM, particularly when combined with PD-1 inhibitors.
- Other names
- collagen-binding anti-GITR antibodyCBD-modified anti-GITR antibody
Beyond the preview
Go deeper on CBD-alphaGITR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBD-alphaGITR.